{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:04:34Z","timestamp":1791839074626,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81972495"],"award-info":[{"award-number":["No. 81972495"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Youth Science Foundation of The First Affiliated Hospital, Zhejiang University School of Medicine"},{"name":"the Department of Science and Technology of Zhejiang Province, \u201cPioneer\u201d and \u201cLeading Goose\u201d R&D Program of Zhejiang"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    BRAF-targeted therapy is a promising strategy for thyroid cancer. However, its efficacy is limited by drug resistance. This study elucidates the role of fatty acid oxidation (FAO) in mediating adaptive resistance to BRAF\n                    <jats:sup>V600E<\/jats:sup>\n                    inhibition (BRAFi) in thyroid cancer. Through integrated transcriptomic and metabolomic analyses, we demonstrate that BRAFi by vemurafenib (PLX4032) significantly enhances FAO in thyroid cancer cells. The pharmacological inhibition of FAO via thioridazine (Thio) synergizes with BRAFi to suppress tumor growth in vitro, in vivo and in a patient-derived organoid. Mechanistically, this metabolic shift is driven by the upregulation of PGC1\u03b1, which enhances FAO. The consequent increase in intracellular acetyl-CoA reprograms the histone H3K9 acetylation (H3K9ac) landscape, thereby epigenetically activating pro-survival genes such as RUNX1. In addition, higher expression of RUNX1 correlates with poorer prognosis in thyroid cancer. Consistently, functional studies confirm RUNX1\u2019s oncogenic role, as its knockdown reduces cell proliferation, migration, and invasion. In conclusion, our work reveals a metabolic-epigenetic axis underlying adaptive response to BRAFi and identifies RUNX1 as a novel oncogene in thyroid cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08575-7","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:34:33Z","timestamp":1774031673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-3900","authenticated-orcid":false,"given":"Xumeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1207-7449","authenticated-orcid":false,"given":"Jinghao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-9017","authenticated-orcid":false,"given":"Lisong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-5486","authenticated-orcid":false,"given":"Weibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"8575_CR1","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1097\/CM9.0000000000003284","volume":"137","author":"Z Lyu","year":"2024","unstructured":"Lyu Z, Zhang Y, Sheng C, Huang Y, Zhang Q, Chen K. Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN. Chin Med J. 2024;137:2567\u201376.","journal-title":"Chin Med J"},{"key":"8575_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejso.2017.09.019","volume":"44","author":"N Janjua","year":"2018","unstructured":"Janjua N, Wreesmann VB. Aggressive differentiated thyroid cancer. Eur J Surg Oncol. 2018;44:367\u201377.","journal-title":"Eur J Surg Oncol"},{"key":"8575_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ecl.2021.11.020","volume":"51","author":"A Maniakas","year":"2022","unstructured":"Maniakas A, Zafereo M, Cabanillas ME. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am. 2022;51:391\u2013401.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"8575_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CCO.0000000000000797","volume":"34","author":"RS Scheffel","year":"2022","unstructured":"Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022;34:9\u201318.","journal-title":"Curr Opin Oncol"},{"key":"8575_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112570","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Carvajal R, Kim M, Yang HW. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF\/MEK inhibition in melanoma. Cell Rep. 2023;42:112570.","journal-title":"Cell Rep"},{"key":"8575_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215799","volume":"543","author":"Y Shimizu","year":"2022","unstructured":"Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, et al. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Cancer Lett. 2022;543:215799.","journal-title":"Cancer Lett"},{"key":"8575_CR7","doi-asserted-by":"crossref","unstructured":"Proietti I, Skroza N, Bernardini N, Tolino E, Balduzzi V, Marchesiello A, et al. Mechanisms of acquired Braf inhibitor resistance in melanoma: a systematic review. Cancers. 2020;12:2801.","DOI":"10.3390\/cancers12102801"},{"key":"8575_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","volume":"4","author":"TJ Parmenter","year":"2014","unstructured":"Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423\u201333.","journal-title":"Cancer Discov"},{"key":"8575_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1210\/jc.2016-1999","volume":"102","author":"W Wang","year":"2017","unstructured":"Wang W, Kang H, Zhao Y, Min I, Wyrwas B, Moore M, et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab. 2017;102:634\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"8575_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.tranon.2019.10.007","volume":"13","author":"S Chen","year":"2020","unstructured":"Chen S, Su X, Jiang X, Zhang T, Min I, Ding Y, et al. VCAM-1 upregulation contributes to insensitivity of vemurafenib in BRAF-mutant thyroid cancer. Transl Oncol. 2020;13:441\u201351.","journal-title":"Transl Oncol"},{"key":"8575_CR11","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Investig. 2019;129:3006\u201317.","journal-title":"J Clin Investig"},{"key":"8575_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/clinem\/dgae601","volume":"110","author":"J Yuan","year":"2025","unstructured":"Yuan J, Chen Z, Zhang J, Chen X, Chen S, Wang X, et al. Preoperative serum lipids as novel predictors of survival in 3575 patients with papillary thyroid cancer. J Clin Endocrinol Metab. 2025;110:668\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"8575_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.canlet.2018.08.006","volume":"435","author":"Y Ma","year":"2018","unstructured":"Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, et al. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92\u2013100.","journal-title":"Cancer Lett"},{"key":"8575_CR14","doi-asserted-by":"crossref","unstructured":"Xiao L, Ma X, Ye L, Su P, Xiong W, Bi E, et al. IL-9\/STAT3\/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity. J Clin Investig. 2022;132:e153247.","DOI":"10.1172\/JCI153247"},{"key":"8575_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202956","volume":"10","author":"J Li","year":"2023","unstructured":"Li J, Xia Q, Di C, Li C, Si H, Zhou B, et al. Tumor cell-intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid beta-oxidation. Adv Sci. 2023;10:e2202956.","journal-title":"Adv Sci"},{"key":"8575_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","volume":"13","author":"L Sun","year":"2022","unstructured":"Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13:877\u2013919.","journal-title":"Protein Cell"},{"key":"8575_CR17","doi-asserted-by":"crossref","unstructured":"Wang X, Ying T, Yuan J, Wang Y, Su X, Chen S, et al. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation. Endocr Relat Cancer 2023;30:e220344.","DOI":"10.1530\/ERC-22-0344"},{"key":"8575_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188837","volume":"1878","author":"W He","year":"2023","unstructured":"He W, Li Q, Li X. Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188837.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8575_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406\u201315.","journal-title":"Ann Oncol"},{"key":"8575_CR20","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/1078-0432.CCR-19-0253","volume":"25","author":"A Aloia","year":"2019","unstructured":"Aloia A, Mullhaupt D, Chabbert CD, Eberhart T, Fluckiger-Mangual S, Vukolic A, et al. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated melanoma to MAPK inhibitors. Clin Cancer Res. 2019;25:6852\u201367.","journal-title":"Clin Cancer Res"},{"key":"8575_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155285","volume":"124","author":"J Liao","year":"2024","unstructured":"Liao J, Xie X, Wang N, Wang Y, Zhao J, Chen F, et al. Formononetin promotes fatty acid beta-oxidation to treat non-alcoholic steatohepatitis through SIRT1\/PGC-1alpha\/PPARalpha pathway. Phytomedicine. 2024;124:155285.","journal-title":"Phytomedicine"},{"key":"8575_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-023-02814-x","volume":"42","author":"C She","year":"2023","unstructured":"She C, Wu C, Guo W, Xie Y, Li S, Liu W, et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP\/PERK\/eIF2alpha-axis-mediated endoplasmic reticulum stress. J Exp Clin Cancer Res. 2023;42:238.","journal-title":"J Exp Clin Cancer Res"},{"key":"8575_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00211","volume":"39","author":"RL Smith","year":"2018","unstructured":"Smith RL, Soeters MR, Wust RCI, Houtkooper RH. Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. Endocr Rev. 2018;39:489\u2013517.","journal-title":"Endocr Rev"},{"key":"8575_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17:6.","journal-title":"J Hematol Oncol"},{"key":"8575_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","volume":"183","author":"S Shen","year":"2020","unstructured":"Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors. Cell. 2020;183:860\u201374.","journal-title":"Cell"},{"key":"8575_CR26","doi-asserted-by":"crossref","unstructured":"Sultana A, Reilly J, Fenton M. Thioridazine for schizophrenia. Cochrane Database Syst Rev. 2000:3:CD001944.","DOI":"10.1002\/14651858.CD001944"},{"key":"8575_CR27","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/bloodadvances.2018015677","volume":"2","author":"L Aslostovar","year":"2018","unstructured":"Aslostovar L, Boyd AL, Almakadi M, Collins TJ, Leong DP, Tirona RG, et al. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Adv. 2018;2:1935\u201345.","journal-title":"Blood Adv"},{"key":"8575_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41416-023-02557-8","volume":"130","author":"CY Mah","year":"2024","unstructured":"Mah CY, Nguyen ADT, Niijima T, Helm M, Dehairs J, Ryan FJ, et al. Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer. Br J Cancer. 2024;130:741\u201354.","journal-title":"Br J Cancer"},{"key":"8575_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108421","volume":"33","author":"S Shen","year":"2020","unstructured":"Shen S, Faouzi S, Souquere S, Roy S, Routier E, Libenciuc C, et al. Melanoma persister cells are tolerant to BRAF\/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 2020;33:108421.","journal-title":"Cell Rep"},{"key":"8575_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32101-w","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan Y, Li J, Zhao G, Huang KC, C\u00e1rdenas H, Wang Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13:4554.","journal-title":"Nat Commun"},{"key":"8575_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122763","volume":"350","author":"J Yu","year":"2024","unstructured":"Yu J, Du Y, Liu C, Xie Y, Yuan M, Shan M, et al. Low GPR81 in ER(+) breast cancer cells drives tamoxifen resistance through inducing PPARalpha-mediated fatty acid oxidation. Life Sci. 2024;350:122763.","journal-title":"Life Sci"},{"key":"8575_CR32","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.7150\/jca.30018","volume":"10","author":"CL Liu","year":"2019","unstructured":"Liu CL, Yang PS, Wang TY, Huang SY, Kuo YH, Cheng SP. PGC1alpha downregulation and glycolytic phenotype in thyroid cancer. J Cancer. 2019;10:3819\u201329.","journal-title":"J Cancer"},{"key":"8575_CR33","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/febs.14786","volume":"286","author":"Y Gao","year":"2019","unstructured":"Gao Y, Yang F, Yang XA, Zhang L, Yu H, Cheng X, et al. Mitochondrial metabolism is inhibited by the HIF1alpha-MYC-PGC-1beta axis in BRAF V600E thyroid cancer. FEBS J. 2019;286:1420\u201336.","journal-title":"FEBS J"},{"key":"8575_CR34","doi-asserted-by":"crossref","unstructured":"Abu Shelbayeh O, Arroum T, Morris S, Busch KB. PGC-1alpha is a master regulator of mitochondrial lifecycle and ROS stress response. Antioxidants. 2023;12:1075.","DOI":"10.3390\/antiox12051075"},{"key":"8575_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/cvr\/cvq080","volume":"87","author":"D Alvarez-Guardia","year":"2010","unstructured":"Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, Feldman AM, et al. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res. 2010;87:449\u201358.","journal-title":"Cardiovasc Res"},{"key":"8575_CR36","doi-asserted-by":"crossref","unstructured":"Jimenez-Mora E, Gallego B, Diaz-Gago S, Lasa M, Baquero P, Chiloeches A. (V600E)BRAF inhibition induces cytoprotective autophagy through AMPK in thyroid cancer cells. Int J Mol Sci 2021;22:6033.","DOI":"10.3390\/ijms22116033"},{"key":"8575_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150161","volume":"722","author":"J Du","year":"2024","unstructured":"Du J, Yi X, Guo S, Wang H, Shi Q, Zhang J, et al. SIRT7 promotes mitochondrial biogenesis to render the adaptive resistance to MAPK inhibition in melanoma. Biochem Biophys Res Commun. 2024;722:150161.","journal-title":"Biochem Biophys Res Commun"},{"key":"8575_CR38","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.onc.1209994","volume":"26","author":"J Liu","year":"2007","unstructured":"Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, et al. Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007;26:1954\u20138.","journal-title":"Oncogene"},{"key":"8575_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013;23:302\u201315.","journal-title":"Cancer Cell"},{"key":"8575_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.654569","volume":"12","author":"A Lopez-Marquez","year":"2021","unstructured":"Lopez-Marquez A, Carrasco-Lopez C, Fernandez-Mendez C, Santisteban P. Unraveling the complex interplay between transcription factors and signaling molecules in thyroid differentiation and function, from embryos to adults. Front Endocrinol. 2021;12:654569.","journal-title":"Front Endocrinol"},{"key":"8575_CR41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cmet.2025.01.013","volume":"37","author":"PA Dumesic","year":"2025","unstructured":"Dumesic PA, Wilensky SE, Bose S, Van Vranken JG, Gygi SP, Spiegelman BM. RBM43 controls PGC1alpha translation and a PGC1alpha-STING signaling axis. Cell Metab. 2025;37:742\u201357.e748.","journal-title":"Cell Metab"},{"key":"8575_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28705-x","volume":"13","author":"LK Smith","year":"2022","unstructured":"Smith LK, Parmenter T, Kleinschmidt M, Kusnadi EP, Kang J, Martin CA, et al. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma. Nat Commun. 2022;13:1100.","journal-title":"Nat Commun"},{"key":"8575_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41568-022-00543-5","volume":"23","author":"DA Guertin","year":"2023","unstructured":"Guertin DA, Wellen KE. Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023;23:156\u201372.","journal-title":"Nat Rev Cancer"},{"key":"8575_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110870","volume":"39","author":"YJ Li","year":"2022","unstructured":"Li YJ, Fahrmann JF, Aftabizadeh M, Zhao Q, Tripathi SC, Zhang C, et al. Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. Cell Rep. 2022;39:110870.","journal-title":"Cell Rep"},{"key":"8575_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","volume":"23","author":"M Shvedunova","year":"2022","unstructured":"Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022;23:329\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8575_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41420-023-01700-x","volume":"9","author":"MB Gayatri","year":"2023","unstructured":"Gayatri MB, Kancha RK, Behera A, Patchva D, Velugonda N, Gundeti S, et al. AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcomes imatinib resistance in chronic myelogenous leukemia (CML) subjects. Cell Death Discov. 2023;9:401.","journal-title":"Cell Death Discov"},{"key":"8575_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s11658-024-00610-9","volume":"29","author":"S Ma","year":"2024","unstructured":"Ma S, Xu Y, Qin X, Tao M, Gu X, Shen L, et al. RUNX1, FUS, and ELAVL1-induced circPTPN22 promote gastric cancer cell proliferation, migration, and invasion through miR-6788-5p\/PAK1 axis-mediated autophagy. Cell Mol Biol Lett. 2024;29:95.","journal-title":"Cell Mol Biol Lett"},{"key":"8575_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114116","volume":"180","author":"L Xiao","year":"2020","unstructured":"Xiao L, Peng Z, Zhu A, Xue R, Lu R, Mi J, et al. Inhibition of RUNX1 promotes cisplatin-induced apoptosis in ovarian cancer cells. Biochem Pharmacol. 2020;180:114116.","journal-title":"Biochem Pharmacol"},{"key":"8575_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06481-4","volume":"15","author":"X Cui","year":"2024","unstructured":"Cui X, Huo D, Wang Q, Wang Y, Liu X, Zhao K, et al. RUNX1\/NPM1\/H3K4me3 complex contributes to extracellular matrix remodeling via enhancing FOSL2 transcriptional activation in glioblastoma. Cell Death Dis. 2024;15:98.","journal-title":"Cell Death Dis"},{"key":"8575_CR50","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/jcp.24989","volume":"230","author":"G Browne","year":"2015","unstructured":"Browne G, Taipaleenmaki H, Bishop NM, Madasu SC, Shaw LM, van Wijnen AJ, et al. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice, and its depletion in vitro inhibits migration and invasion. J Cell Physiol. 2015;230:2522\u201332.","journal-title":"J Cell Physiol"},{"key":"8575_CR51","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2217\/epi-2023-0338","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Yin Y, Huang H, Li M, Li H, Zhang M, et al. RUNX1 methylation as a cancer biomarker in differentiating papillary thyroid cancer from benign thyroid nodules. Epigenomics. 2023;15:1257\u201372.","journal-title":"Epigenomics"},{"key":"8575_CR52","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10495-012-0717-2","volume":"17","author":"S Kang","year":"2012","unstructured":"Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ, et al. Thioridazine induces apoptosis by targeting the PI3K\/Akt\/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012;17:989\u201397.","journal-title":"Apoptosis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08575-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08575-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08575-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:44Z","timestamp":1774987364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08575-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8575"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08575-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6898631\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Zhejiang University (reference number: 2025B0851) and was conducted in accordance with the Declaration of Helsinki. The animal experiments were approved by the Animal Experimental Ethical Inspection of the First Affiliated Hospital, Zhejiang University School of Medicine (reference number: 2019332). All methods in the study were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"329"}}